MedPath

Central nervous effects of Exenatide i.v. vs. NaCl 0.9% on regulation of hunger and satiety in obesity and type 2 diabetes: an fMRI study. Amendment 1: increase of dosage

Phase 2
Recruiting
Conditions
E66
Obesity
Registration Number
DRKS00000301
Lead Sponsor
niversität Leipzig
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Male
Target Recruitment
20
Inclusion Criteria

BMI > 30 kg/m2
nonsmoking
right handed
German speaking
Vision (also corrected) intact

Exclusion Criteria

chronic diseases except art. hypertension and hyperlipidemia
medication except antihypertensives and lipid lowering agents
implanted metallic objects
cardiac arrhythmia
eating disorders
vegetarians/ vegans
smokers
addiction to alcohol
claustrophobia
alterations of blood count
increase of liver values

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
o defined endpoint for fMRI-trial. Analysis is performed descriptive and explorative.<br><br>It will be assessed:<br>Brain activation (BOLD-response)<br>blood samples: glucose, insulin, GLP-1, Ghrelin, exenatide<br>state of hunger (by visual analogue scale)<br>energy uptake in free buffet
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath